» Articles » PMID: 23560111

Leukemia Mediated Endothelial Cell Activation Modulates Leukemia Cell Susceptibility to Chemotherapy Through a Positive Feedback Loop Mechanism

Overview
Journal PLoS One
Date 2013 Apr 6
PMID 23560111
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

In acute myeloid leukemia (AML), the chances of achieving disease-free survival are low. Studies have demonstrated a supportive role of endothelial cells (ECs) in normal hematopoiesis. Here we show that similar intercellular relationships exist in leukemia. We demonstrate that leukemia cells themselves initiate these interactions by directly modulating the behavior of resting ECs through the induction of EC activation. In this inflammatory state, activated ECs induce the adhesion of a sub-set of leukemia cells through the cell adhesion molecule E-selectin. These adherent leukemia cells are sequestered in a quiescent state and are unaffected by chemotherapy. The ability of adherent cells to later detach and again become proliferative following exposure to chemotherapy suggests a role of this process in relapse. Interestingly, differing leukemia subtypes modulate this process to varying degrees, which may explain the varied response of AML patients to chemotherapy and relapse rates. Finally, because leukemia cells themselves induce EC activation, we postulate a positive-feedback loop in leukemia that exists to support the growth and relapse of the disease. Together, the data defines a new mechanism describing how ECs and leukemia cells interact during leukemogenesis, which could be used to develop novel treatments for those with AML.

Citing Articles

A Novel In Vitro Model of the Bone Marrow Microenvironment in Acute Myeloid Leukemia Identifies CD44 and Focal Adhesion Kinase as Therapeutic Targets to Reverse Cell Adhesion-Mediated Drug Resistance.

Ladikou E, Sharp K, Simoes F, Jones J, Burley T, Stott L Cancers (Basel). 2025; 17(1.

PMID: 39796762 PMC: 11719579. DOI: 10.3390/cancers17010135.


In vivo monitoring of leukemia-niche interactions in a zebrafish xenograft model.

Arner A, Ettinger A, Blaser B, Schmid B, Jeremias I, Rostam N PLoS One. 2024; 19(8):e0309415.

PMID: 39213296 PMC: 11364250. DOI: 10.1371/journal.pone.0309415.


Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?.

Uy G, DeAngelo D, Lozier J, Fisher D, Jonas B, Magnani J Blood Rev. 2024; 65:101184.

PMID: 38493006 PMC: 11051645. DOI: 10.1016/j.blre.2024.101184.


Tumor Angiocrine Signaling: Novel Targeting Opportunity in Cancer.

Oria V, Erler J Cells. 2023; 12(20).

PMID: 37887354 PMC: 10605017. DOI: 10.3390/cells12202510.


Doxorubicin Activity Is Modulated by Traditional Herbal Extracts in a 2D and 3D Multicellular Sphere Model of Leukemia.

Corzo Parada L, Uruena C, Leal-Garcia E, Barreto A, Ballesteros-Ramirez R, Rodriguez-Pardo V Pharmaceutics. 2023; 15(6).

PMID: 37376139 PMC: 10302921. DOI: 10.3390/pharmaceutics15061690.


References
1.
Madlambayan G, Meacham A, Hosaka K, Mir S, Jorgensen M, Scott E . Leukemia regression by vascular disruption and antiangiogenic therapy. Blood. 2010; 116(9):1539-47. PMC: 2938842. DOI: 10.1182/blood-2009-06-230474. View

2.
Hussong J, Rodgers G, Shami P . Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 1999; 95(1):309-13. View

3.
Sipkins D, Wei X, Wu J, Runnels J, Cote D, Means T . In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005; 435(7044):969-73. PMC: 2570168. DOI: 10.1038/nature03703. View

4.
Kuldo J, Ogawara K, Werner N, Asgeirsdottir S, Kamps J, Kok R . Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. Curr Vasc Pharmacol. 2005; 3(1):11-39. DOI: 10.2174/1570161052773898. View

5.
Ohyama C, Tsuboi S, Fukuda M . Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells. EMBO J. 1999; 18(6):1516-25. PMC: 1171240. DOI: 10.1093/emboj/18.6.1516. View